<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lanthanum: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lanthanum: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lanthanum: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11776" href="/d/html/11776.html" rel="external">see "Lanthanum: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F186951"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Fosrenol</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867321"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Fosrenol;</li>
<li>NAT-Lanthanum</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F186966"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Phosphate Binder</li></ul></div>
<div class="block doa drugH1Div" id="F186953"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Use in combination with dietary phosphate restriction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="260f20d5-597c-46c0-b39a-7bd210352f76">Hyperphosphatemia in chronic kidney disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperphosphatemia in chronic kidney disease, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 1,500 mg/day in divided doses taken with or immediately after meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Dosage adjustment: Increase or decrease dose by 250 or 500 mg per meal at 2- to 3-week intervals as needed to obtain targeted serum phosphorus concentrations; usual dosage range: 1,500 to 3,000 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29989014','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29989014','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992104"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary. </p></div>
<div class="block doha drugH1Div" id="F50989344"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F186954"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F186927"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (oral powder: ≤18%; chewable tablets: ≤7%), nausea (oral powder: ≤18%; chewable tablet: ≤11%), vomiting (oral powder: ≤18%; chewable tablets: ≤9%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (chewable tablet: 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Accidental injury (tooth injury with chewable tablets), allergic skin reaction, constipation, dyspepsia, fecal impaction, gastrointestinal perforation, hypophosphatemia, intestinal obstruction (including ileus and subileus), intestinal perforation</p></div>
<div class="block coi drugH1Div" id="F186939"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Bowel obstruction, fecal impaction, ileus</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to lanthanum carbonate or any component of the formulation; hypophosphatemia</p></div>
<div class="block war drugH1Div" id="F186925"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI obstruction: Serious GI obstruction, ileus, subileus, GI perforation, and fecal impaction have been reported, some requiring surgery or hospitalization. Risk factors include patients with altered GI anatomy (eg, diverticular disease, peritonitis, history of GI surgery, GI cancer, GI ulceration), hypomotility disorders (eg, constipation, ileus, subileus, diabetic gastroparesis), or medications known to potentiate effects; may also occur in patients without history of GI disease. Monitor patients closely for GI symptoms (eg, constipation, abdominal pain, abdominal distention); consider discontinuation in patients with unexplained severe GI symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Biliary obstruction: Use with caution in patients with biliary obstruction (elimination of lanthanum may be reduced in these patients).</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Use with caution in patients with active peptic ulcer, ulcerative colitis, or Crohn disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment (elimination of lanthanum may be reduced in these patients).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Tablet: Chew thoroughly to decrease risk of serious adverse GI effects; do not swallow whole.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abdominal x-rays: Lanthanum has radio-opaque properties; may appear as an imaging agent on abdominal x-ray. Product residue has been reported during endoscopic imaging.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bone deposition: Rising lanthanum levels were observed in bone biopsies of patients treated for up to 4.5 years. Lanthanum deposits into developing bone, including growth plates; consequences on developing bone are not known. Use in children is not recommended.</p></div>
<div class="block foc drugH1Div" id="F186934"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fosrenol: 750 mg (10 ea, 90 ea); 1000 mg (10 ea, 90 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fosrenol: 500 mg, 750 mg, 1000 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg, 750 mg, 1000 mg</p></div>
<div class="block geq drugH1Div" id="F186923"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F186941"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Fosrenol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $14.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $14.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $14.41</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Lanthanum Carbonate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $3.96 - $13.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $4.50 - $13.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $4.06 - $13.69</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Fosrenol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $14.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $14.41</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867322"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fosrenol: 250 mg [DSC], 500 mg, 750 mg, 1000 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg, 750 mg, 1000 mg</p></div>
<div class="block adm drugH1Div" id="F186936"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with or immediately after meals. Consider separating administration of oral medications from lanthanum when reduced bioavailability would significantly affect the concomitant medication's safety or efficacy; duration of separation varies based on absorption characteristics and whether it is an IR or ER product; monitor clinical response and/or blood concentrations of concomitant medications with a narrow therapeutic range.</p>
<p style="text-indent:-2em;margin-left:2em;">Chewable tablet: Tablet should be chewed completely prior to swallowing; do not swallow whole. Tablet may be crushed to aid in chewing. Unchewed or incompletely chewed tablets may cause serious GI complications.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral powder: Sprinkle powder on a small quantity of applesauce or other similar food (not liquid) and administer immediately. Do not store for future use.</p></div>
<div class="block meg drugH1Div" id="F13247742"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:0em;margin-left:2em;">Fosrenol: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021468s024%2C204734s006lbl.pdf%23page%3D12&amp;token=ESvJ%2B7pUrKlCz1gcbRfO8%2BwPzI92baMHRJDerJFd%2BVNDl2pDXmEiUIDIYLalMHCA95nlqqO5rfXNG2Rx1AHZYu2Ug1nXeHTRGkuVDJgeaffHklf9jQMeo2vehaz6SXAE&amp;TOPIC_ID=10219" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021468s024,204734s006lbl.pdf#page=12</a></p></div>
<div class="block use drugH1Div" id="F186935"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hyperphosphatemia in chronic kidney disease, treatment:</b> Reduction of serum phosphate in patients with end-stage kidney disease.</p></div>
<div class="block mst drugH1Div" id="F7914236"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lanthanum may be confused with lithium.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299576"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F186928"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ampicillin: Lanthanum may decrease the serum concentration of Ampicillin.  Management: Administer oral ampicillin at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Lanthanum may decrease the serum concentration of Angiotensin-Converting Enzyme Inhibitors.  Management: Administer angiotensin-converting enzyme (ACE) inhibitors at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May diminish the therapeutic effect of Lanthanum. Management: Administer antacid products at least 2 hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacampicillin: Lanthanum may decrease the serum concentration of Bacampicillin.  Management: Administer bacampicillin at least 2 hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: Lanthanum may decrease the serum concentration of Chloroquine.  Management: Administer chloroquine at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: Lanthanum may decrease the serum concentration of Halofantrine.  Management: Administer halofantrine at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HMG-CoA Reductase Inhibitors (Statins): Lanthanum may decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins).  Management: Administer HMG-CoA reductase inhibitors (eg, statins) at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Lanthanum may decrease the serum concentration of Quinolones.  Management: Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Lanthanum may decrease the serum concentration of Tetracyclines.  Management: Administer oral tetracycline antibiotics at least 2 hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Lanthanum may decrease the serum concentration of Thyroid Products.  Management: Separate the administration of thyroid products and lanthanum by at least 4 hours.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F186942"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Environmental studies suggest lanthanum may cross the placenta (Huo 2017).</p>
<p style="text-indent:0em;margin-top:2em;">If a reduction of serum phosphate is needed in pregnant patients with end-stage renal disease, agents other than lanthanum are preferred. Discontinuation of phosphate binders may be required in patients on intensified hemodialysis during pregnancy (Burgner 2019; Hladunewich 2016; Tangren 2018; Wiles 2019).</p></div>
<div class="block brc drugH1Div" id="F20547661"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if lanthanum is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, use of a non-lanthanum phosphate binder is recommended in patients who are breastfeeding.</p></div>
<div class="block dic drugH1Div" id="F2886994"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;text-align:justify;display:inline">Take  with or immediately after meals.</p></div>
<div class="block mop drugH1Div" id="F186932"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Serum calcium, phosphorus, and parathyroid hormone (PTH): Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of chronic kidney disease (CKD), and the use of treatments for chronic kidney disease-mineral and bone disorder (CKD-MBD) (KDIGO 2017):</p>
<p style="text-indent:-2em;margin-left:4em;">CKD stage G3a to G3b: Serum calcium and phosphate: Every 6 to 12 months; PTH: Frequency based on baseline level and progression of CKD</p>
<p style="text-indent:-2em;margin-left:4em;">CKD stage G4: Serum calcium and phosphate: Every 3 to 6 months; PTH: Every 6 to 12 months</p>
<p style="text-indent:-2em;margin-left:4em;">CKD stage G5 and G5D: Serum calcium and phosphate: Every 1 to 3 months; PTH: Every 3 to 6 months</p></div>
<div class="block rer drugH1Div" id="F2886993"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Due to the complexity and interdependency of the laboratory parameters used for therapeutic decisions in chronic kidney disease-mineral and bone disorder (CKD-MBD) patients, serial assessments of phosphate, calcium, and parathyroid hormone (PTH) levels should be considered together (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Calcium (total): Normal range: Adults: 8.5 to 10.5 m/dL (2.12 to 2.62 mmol/L) (IOM 2011). Avoid hypercalcemia for chronic kidney disease (CKD) stages G3a to G5D (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Phosphorus: 2.5 to 4.5 mg/dL (0.81 to 1.45 mmol/L). Lower elevated phosphorus levels toward the normal range for CKD stages G3a to G5D (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">PTH:</p>
<p style="text-indent:-2em;margin-left:6em;">CKD stage G3a to G5: Optimal PTH level is unknown; evaluate patients with progressively elevated intact PTH levels or if levels are consistently above the normal range (assay-dependent) (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">Dialysis patients: Maintain intact parathyroid hormone (iPTH) within 2 to 9 times the upper limit of normal for the assay used (KDIGO 2017).</p></div>
<div class="block pha drugH1Div" id="F186924"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Disassociates in the upper gastrointestinal tract to lanthanum ions (La<sup>3+</sup>) which bind to dietary phosphate resulting in insoluble lanthanum phosphate complexes and a net decrease in serum phosphate and calcium levels.</p></div>
<div class="block phk drugH1Div" id="F186938"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: &lt;0.002%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: &gt;99% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Not metabolized </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Plasma: 53 hours; Bone: 2-3.6 years </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces primarily; urine &lt;2%</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539886"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol | Lanthan Mylan</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Calafos | Fosrenol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol | Lanthane mylan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol | Lanthanum</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Foznol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Fosbait | Foschek | Fosend</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Foznol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol | Lanthanum carbonate towa | Lanthanum carbonate yd</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Calafos | Fosrenol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol | Lanthaan mylan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol | Lanthanum mylan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Antax</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Fosrenol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-15199290">
<a name="15199290"></a>Behets GJ, Verberckmoes SC, D'Haese PC, et al. Lanthanum Carbonate: A New Phosphate Binder. <i>Curr Opin Nephrol Hypertens</i>. 2004;13:403-409.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanthanum-drug-information/abstract-text/15199290/pubmed" id="15199290" target="_blank">15199290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31221529">
<a name="31221529"></a>Burgner A, Hladunewich MA. Women's reproductive health for the nephrologist. <i>Am J Kidney Dis</i>. 2019;74(5):675-681. doi:10.1053/j.ajkd.2019.04.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanthanum-drug-information/abstract-text/31221529/pubmed" id="31221529" target="_blank">31221529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fosrenol.1">
<a name="Fosrenol.1"></a>Fosrenol (lanthanum) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fosrenol.2">
<a name="Fosrenol.2"></a>Fosrenol (lanthanum) [product monograph]. Toronto, Ontario, Canada: Takeda Canada Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27061443">
<a name="27061443"></a>Hladunewich M, Schatell D. Intensive dialysis and pregnancy. <i>Hemodial Int</i>. 2016;20(3):339-348. doi:10.1111/hdi.12420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanthanum-drug-information/abstract-text/27061443/pubmed" id="27061443" target="_blank">27061443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28411498">
<a name="28411498"></a>Huo W, Zhu Y, Li Z, Pang Y, Wang B, Li Z. A pilot study on the association between rare earth elements in maternal hair and the risk of neural tube defects in north China. <i>Environ Pollut</i>. 2017;226:89‐93. doi:10.1016/j.envpol.2017.03.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanthanum-drug-information/abstract-text/28411498/pubmed" id="28411498" target="_blank">28411498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>Institute of Medicine (IOM). <i>Dietary Reference Intakes for Calcium and Vitamin D</i>. The National Academies Press; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). <i>Kidney Int</i>. 2017;7(suppl 1):1-59. doi:10.1016/j.kisu.2017.04.001</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29989014">
<a name="29989014"></a>Kovesdy CP, Lu JL, Wall BM, et al. Changes with lanthanum carbonate, calcium acetate, and phosphorus restriction in CKD: a randomized controlled trial. <i>Kidney Int Rep</i>. 2018;3(4):897-904. doi:10.1016/j.ekir.2018.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanthanum-drug-information/abstract-text/29989014/pubmed" id="29989014" target="_blank">29989014</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lanthanum carbonate chewable tablets [prescribing information]. Warren , NJ: Cipla USA Incl; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29478065">
<a name="29478065"></a>Tangren J, Nadel M, Hladunewich MA. Pregnancy and end-stage renal disease. <i>Blood Purif</i>. 2018;45(1-3):194-200. doi:10.1159/000485157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanthanum-drug-information/abstract-text/29478065/pubmed" id="29478065" target="_blank">29478065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30606688">
<a name="30606688"></a>Wiles K, de Oliveira L. Dialysis in pregnancy. <i>Best Pract Res Clin Obstet Gynaecol</i>. 2019;57:33-46. doi:10.1016/j.bpobgyn.2018.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lanthanum-drug-information/abstract-text/30606688/pubmed" id="30606688" target="_blank">30606688</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10219 Version 207.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
